Netramark comments on US executive order

NetraMark Holdings Inc. has commented on a recent U.S. executive order aimed at accelerating treatments for serious mental illnesses. The company highlighted the critical need for regulatory-grade trial design in the development of psychedelic therapies. This focus underscores the growing intersection of mental health treatment innovation and the stringent requirements of clinical research. Netramark's statement emphasizes the importance of robust scientific methodology as the field progresses towards potential new therapeutic avenues.